期刊文献+

扩张型心肌病患者经标准药物治疗后左心室射血分数恢复正常的发生率及预测因素分析 被引量:40

Occurrence and Predictor Analysis for the Recovery of Left Ventricular Ejection Fraction in Patients With Dilated Cardiomyopathy After Standard Medication
下载PDF
导出
摘要 目的:分析扩张型心肌病患者经标准药物治疗后左心室射血分数(LVEF)恢复正常的发生率及其预测因素。方法:入选2008-10至2013-10在阜外心血管病医院心力衰竭(心衰)病房住院接受标准抗心衰药物治疗的扩张型心肌病患者,出院后随访至2014-09或发生全因死亡或心脏移植。根据复查超声心动图结果,定义随访LVEF绝对值较基线至少提高10%且LVEF>50%为恢复正常标准。调查抗心衰药物治疗下扩张型心肌病患者LVEF恢复正常的发生率。根据LVEF恢复情况分为LVEF恢复组和LVEF未恢复组。收集患者首次入院时的临床和超声心动图指标,采用多变量Logistic回归分析方法分析LVEF恢复正常的基线预测指标。以全因死亡或心脏移植为临床终点事件,应用Kaplan-Meier法进行生存分析,两组间比较采用Log-rank检验。结果:共有322例有完整超声心动图随访结果的扩张型心肌病患者纳入本研究分析。超声心动图中位随访25个月后,LVEF恢复组的91例(28.3%)患者LVEF恢复正常,其LVEF由基线时32.1%±6.1%明显提高至58.2%±4.9%(P<0.01),而LVEF未恢复组的231例未恢复患者LVEF仅增加6.7%±8.3%。多变量Logistic回归分析结果显示,患者入院时心衰病史短(≤6个月vs>6个月,OR=0.330,P<0.01)、收缩压水平高[每升高10 mm Hg(1 mm Hg=0.133 k Pa),OR=1.312,P<0.01]、心电图QRS间期短(OR=0.979,P<0.01)、超声心动图测量的左心室舒张末期内径(LVEDD)小(OR=0.960,P<0.01)、LVEF高(OR=1.063,P<0.05)及出院带药应用血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂(OR=2.579,P<0.05)是扩张型心肌病患者LVEF恢复正常的独立预测因素。生存分析结果显示,LVEF恢复正常患者的长期无心脏移植生存率明显高于未恢复患者(P<0.01)。结论:部分扩张型心肌病患者经过标准抗心衰药物治疗后LVEF可以恢复正常,这与患者入院时心衰病史、收缩压水平、心电图QRS间期、超声测量LVEDD和LVEF水平及应用血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂有关。 Objective:To analyze the occurrence and predictor for the recovery of left ventricular ejection fraction(LVEF) in patients with dilated cardiomyopathy(DCM) after standard medication.Methods:We retrospectively studied DCM patients with heart failure(HF) admitted in our hospital from 2008-10 to 2013-10,and a total of 322 patients having entire information were enrolled in this research.All patients receive standard medication and they were followed–up until 2014-09 or until death or heart transplantation after discharge.According to echocardiography,the recovered LVEF was defined as that the absolute value of LVEF must be elevated at least 10% from the baseline and meanwhile,LVEF 〉 50%.The patients were divided into 2 groups based on if their LVEFrecovered to normal level:Recovered group,n =91(28.3%),and Unrecovered group,n =231.The clinical data at admission and the variables by echocardiography as potential relevant factors of LVEF recovery were studied by Logistic regression analysis,the endpoints were all cause death or heart transplantation.Survival analysis was conducted by Kaplan-Meier method and the comparison between 2 groups was done by log-rank test.Results:With a median follow-up period of 25 months,LVEF in Recovered group from(32.1% ± 6.1%) of baseline increased to(58.2%±4.9%),P 〈0.01,while in Unrecovered group,LVEF only increased(6.7% ± 8.3%).Multivariable logistic regression analysis presented that shorter history of HF(≤ 6 months vs 〉 6 months,OR=0.330,P〈0.01),higher systolic blood pressure(per 10 mm Hg elevation,OR=1.312,P 〈0.01),shorter QRS interval(OR=0.979,P 〈0.01),smaller left ventricular end-diastolic diameter(LVEDD)(OR=0.960,P 〈0.01),higher LVEF(OR=1.063,P 〈0.05) and the application of ACEI/ARB upon discharge(OR=2.579,P 〈0.05) were the independent predictors for LVEF recovery.Survival analysis showed that the patients with recovered LVEF had obviously higher survival rate than unrecovered patients,P 〈0.01.Conclusion:With standard medication,a part of DCM patients with HF could have their LVEF recovered to normal level,which related to the history of HF,systolic blood pressure,QRS duration,LVEDD,LVEF and the application of ACEI/ARB upon discharge.
出处 《中国循环杂志》 CSCD 北大核心 2015年第5期417-421,共5页 Chinese Circulation Journal
基金 国家"十二.五"科技支撑计划项目(2011BAI11B02) 首都医学科学发展基金项目(20091005)
关键词 扩张型心肌病 左心室射血分数 恢复 Dilated cardiomyopathy Left ventricular ejection fraction Recovery
  • 相关文献

参考文献22

  • 1Jefferies JL, Towbin JA. Dilated eardiomyopathy. Lancet, 2010, 375: 752-762.
  • 2Steimle AE, Stevenson LW, Fonarow GC, et al. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coil Cardiol, 1994, 23: 553-559.
  • 3Kawai K, Takaoka H, Hata K, et al. Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol, 1999, 84: 671-676.
  • 4Naqvi TZ, Goel RK, Forrester JS, et al. Usefulness of left ventricular mass in predicting recovery of left ventricular systolic function in patients with symptomatic idiopathic dilated cardiomyopathy. Am J Cardiol, 2000, 85: 624-629.
  • 5Cicoira M, Zanolla L, Latina L, et al. Frequency, prognosis and predictors of improvement of systolic left ventricular function in patients with 'classic' clinical diagnosis of idiopathic dilated cardiomyopathy. Eur J Heart Fail, 2001, 3: 323-330.
  • 6Binkley PF, Lesinski A, Ferguson JP, et al. Recovery of normal ventricular function in patients with dilated eardiomyopathy: predictors of an increasingly prevalent clinical event. Am Heart J, 2008, 155: 69- 74.
  • 7McNamara DM, Starling RC, Cooper LT, et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coil Cardiol, 2011, 58: 1112- 1118.
  • 8Merlo M, Pyxaras SA, Pinamonti B, et al. Prevalence and prognostic significance of left ventricular reverse remodeling in dilatedcardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol, 2011, 57: 1468-1476.
  • 9Kim MS, Kim JS, Kim YR, et al. Cerebral blood flow as a marker for recovery of left ventricular systolic dysfunction in patients with idiopathic dilated eardiomyopathy. J Cardiac Fail, 2012, 18: 549-555.
  • 10Choi JO, Kim EY, Lee GY, et al. Predictors of left ventrieular reverse remodeling and subsequent outcomes in nonischemic dilated cardiomyopathy. Cire J, 2013, 77: 462-469.

二级参考文献24

  • 1中华医学会心血管病分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014.中华心血管病杂志,2014,42:98-122.
  • 2Waagestein F,Bristow MR,Swedberg K,et al.Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy[].The Lancet.1993
  • 3Fisher ML,Gottlieb SS,Plotnick GD,et al.Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial[].Journal of the American College of Cardiology.1994
  • 4Gristow MR.Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents[].The American Journal of Cardiology.1993
  • 5Eichhorn EJ,Heesch CM,Risser RC,et al.Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol[].Journal of the American College of Cardiology.1995
  • 6Barnett DB.Beta-blockers in heart failure: a therapeutic paradox[].The Lancet.1994
  • 7Waagestein F,Hjalmarson A,Varnauskas E.Effect of chronic betaadrenergic receptor blokade in congestive cardiomyopathy[].British Heart Journal.1975
  • 8.The CIBIS Scientific Committee:Design of the Cardiac InsufficiencyBisoprolol Study (CIBIS )[].Fundamental and Clinical Pharmacology.1997
  • 9中华医学会心血管病分会,中华心血管病杂志编辑委员会,中国心肌病诊断与治疗建议工作组.心肌病诊断与治疗建议.中华心血管病杂志.2007,35:5-16.
  • 10Joffe SW, Phillips RA. Treating hypertension in patients with left ventrieular dysfunetion: hitting the fairway and avoiding the rough. Curr Heart Fail Rep, 2013, 10: 157-164.

共引文献20

同被引文献296

引证文献40

二级引证文献209

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部